Cancer/Tumor Profiling Market by Technology (Immunoassays, In-Situ Hybridization, Mass Spectrometry), Biomarker Type (Genomic Biomarker, Protein Biomarker), Cancer Type, Application - Global Forecast 2024-2030
Description
Cancer/Tumor Profiling Market by Technology (Immunoassays, In-Situ Hybridization, Mass Spectrometry), Biomarker Type (Genomic Biomarker, Protein Biomarker), Cancer Type, Application - Global Forecast 2024-2030
The Cancer/Tumor Profiling Market size was estimated at USD 10.79 billion in 2023 and expected to reach USD 12.77 billion in 2024, at a CAGR 18.74% to reach USD 35.94 billion by 2030.
Cancer/tumor profiling is a laboratory method that analyzes specific proteins, genes, and other molecules in a tumor to provide information about any genetic or molecular changes, such as gene mutations. Tumor profiling is the technology that oncologists widely use to determine if the pathways of a patient’s tumor match up with available targeted treatments. Accelerated use of biomarkers in the treatment of cancer patients and increasing preference for customized cancer treatments coupled with government and international organization's efforts to develop cancer diagnosis methods support the widespread use of cancer/tumor profiling technologies. On the other hand, high capital investment in cancer/tumor profiling tools and services and low biomarker discovery-to-approval ratio hinders market development. However, the spread of next-generation sequencing, tumor profiling improvements, and point-of-care cancer detection technology expansion is expected to surge their use in the coming years.
Regional Insights
Cancer/tumor profiling market landscape in North America, the EU, GCC, and developed countries across the Asia-Pacific region are highly advanced due to prominent market players and well-established regulatory frameworks and initiatives launched by the governments to reduce cancer burden while improving patient care. Cancer profiling is gradually gaining prominence in developing economies worldwide as investments in cancer diagnostics continue to rise. According to the American Cancer Society, approximately 1.9 million new cancer cases are anticipated to be diagnosed in the United States in 2023, bolstering the need for cancer profiling. Northern and Western European countries observe considerably high use and availability of biomarker testing procedures, reflecting their higher investment in healthcare. Market players across countries are collaborating with technology providers in the United States and European countries and each other to contribute to deploying the advancement in cancer diagnosis, profiling, and treatment procedures. Furthermore, the ongoing campaigns and cancer awareness programs have highlighted the need for cancer/tumor profiling in Asian countries.
Market Insights
- Market Dynamics
The market dynamics represent an ever-changing landscape of the Cancer/Tumor Profiling Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.- Market Drivers
- Increasing adoption of biomarkers to treat cancer patients
- Availability of government and global organizations' initiatives for devising cancer diagnosing methods
- Surging preference for personalized medicines for cancer treatment
- Market Restraints
- High capital investment in cancer/tumor profiling instruments and services
- Market Opportunities
- Emergence of next-generation sequencing and advancements in tumor profiling
- Improvements in point-of-care diagnostic technologies to improve cancer detection
- Market Challenges
- Low biomarker discovery-to-approval ratio
- Market Segmentation Analysis
- Technology: Adoption of next-generation sequencing (NGS) for exploring genetic alterations in various cancers
- Biomarker Type: Use of genomic biomarkers for the measurement of the expression of a gene, the gene function, and the gene regulation
- Cancer Type: Wide preference for cancer profiling in prostate cancers for predictive modeling and clinical risk stratification
- Application: Increasing use of cancer/tumor profiling in developing precision medicine to improve healing and recovery time
- Market Disruption Analysis
- Porter’s Five Forces Analysis
- Value Chain & Critical Path Analysis
- Pricing Analysis
- Technology Analysis
- Patent Analysis
- Trade Analysis
- Regulatory Framework Analysis
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cancer/Tumor Profiling Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cancer/Tumor Profiling Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments- Agilent and NCCS Sign Research Collaboration Agreement to Advance Singapore's Genomic Profiling on Asian-prevalent Cancers
Agilent Technologies Inc. has entered into a Research Collaboration Agreement (RCA) with the National Cancer Centre Singapore to accelerate translational cancer research on Asian-prevalent cancers over the next two years. As part of this agreement, Agilent has supplied an automated NGS library preparation platform, enabling investigations into the genomic details specific to Asian cancer cohorts.
Sophia Genetics, Agilent Partner on Cancer Analysis Product
Sophia Genetics, a leader in data-driven medicine, has recently announced a long-term partnership with Agilent Technologies, allowing them to develop a new cancer analysis product. This new product will enable clinicians to use patient’s genomic profiling information for smarter and more efficient care decisions. Through this endeavor, both companies are working towards making personalized cancer treatments faster and more accessible. With their product, doctors can move from the traditional trial-and-error approach of prescribing drugs to one tailored and precisely matches therapeutic agents to the tumor's genetics. The longer-term research is underway as well, which could help serve as an important resource for future cancer studies.
Point32Health and Foundation Medicine Expand Access to Comprehensive Genomic Profiling for Members with Advanced Cancer
Point32Health and Foundation Medicine have recently taken a major step forward in providing comprehensive genomic profiling for members with advanced cancer. By expanding access to this technology, individuals will now receive tailored treatments that can increase their chances of responding to the therapy needed for successful treatment outcomes. This initiative will increase human-recoded data levels and provide a more personalized approach to cancer treatments, leading the way in providing the best possible care for those fighting the disease. With Foundation Medicine's mission to accelerate precision medicine and Point32Health's dedication to making complex molecular information accessible, these two organizations are positioned as game changers when advancing cancer treatments.
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cancer/Tumor Profiling Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Cancer/Tumor Profiling Market, highlighting leading vendors and their innovative profiles. These include 4basecare Onco Solutions Private Limited, ACT Genomics Co., Ltd. by Prenetics Global Limited, Agendia, Inc., Agilent Technologies, Inc., BostonGene Corporation, Caris Life Sciences, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GENINUS Inc., Genomic Life, GenScript Biotech Corporation, Guardant Health, Inc., Hologic, Inc., HTG Molecular Diagnostics, Inc., Illumina, Inc., IMBdx, Inc., Laboratory Corporation of America Holdings, Lucence Health, Inc., Merck KGaA, NanoString Technologies, Inc., Neogenomics, Inc., Nonacus Limited, OncoDNA S.A., Oncompass Medicine Hungary Kft., Paragon Genomics, Inc., Personalis, Inc., Perthera, Inc., Predictive Oncology Inc., Strand Life Sciences, Sysmex Corporation, Takara Bio Inc., Tempus Labs Inc., and Thermo Fisher Scientific Inc..
Market Segmentation & Coverage
This research report categorizes the Cancer/Tumor Profiling Market to forecast the revenues and analyze trends in each of the following sub-markets:- Technology
- Immunoassays
- In-Situ Hybridization
- Mass Spectrometry
- Microarrays
- Next-Generation Sequencing
- Polymerase Chain Reaction
- Biomarker Type
- Genomic Biomarker
- Protein Biomarker
- Cancer Type
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Melanoma Cancer
- Prostate Cancer
- Application
- Biomarker Discovery
- Clinical Application
- Diagnostics
- Personalized Medicine
- Prognostics
- Research
- Screening
- Treatment & Monitoring
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
Please Note: PDF & Excel + Online Access - 1 Year
- Americas
- Market Drivers
Table of Contents
198 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increasing adoption of biomarkers to treat cancer patients
- 5.1.1.2. Availability of government and global organizations' initiatives for devising cancer diagnosing methods
- 5.1.1.3. Surging preference for personalized medicines for cancer treatment
- 5.1.2. Restraints
- 5.1.2.1. High capital investment in cancer/tumor profiling instruments and services
- 5.1.3. Opportunities
- 5.1.3.1. Emergence of next-generation sequencing and advancements in tumor profiling
- 5.1.3.2. Improvements in point-of-care diagnostic technologies to improve cancer detection
- 5.1.4. Challenges
- 5.1.4.1. Low biomarker discovery-to-approval ratio
- 5.2. Market Segmentation Analysis
- 5.2.1. Technology: Adoption of next-generation sequencing (NGS) for exploring genetic alterations in various cancers
- 5.2.2. Biomarker Type: Use of genomic biomarkers for the measurement of the expression of a gene, the gene function, and the gene regulation
- 5.2.3. Cancer Type: Wide preference for cancer profiling in prostate cancers for predictive modeling and clinical risk stratification
- 5.2.4. Application: Increasing use of cancer/tumor profiling in developing precision medicine to improve healing and recovery time
- 5.3. Market Trend Analysis
- 5.3.1. Government initiatives for cancer diagnostics with rapid advancements in cancer/tumor profiling solutions
- 5.3.2. Rising cancer prevalence with evolving cancer research initiatives enhancing the need for novel cancer/tumor profiling in the APAC region
- 5.3.3. Increasing adoption of precision medicines and genetic profiling solutions to overcome the cancer burden across EMEA region
- 5.4. Cumulative Impact of Russia-Ukraine Conflict
- 5.5. Cumulative Impact of High Inflation
- 5.6. Porter’s Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
- 5.7. Value Chain & Critical Path Analysis
- 5.8. Regulatory Framework Analysis
- 6. Cancer/Tumor Profiling Market, by Technology
- 6.1. Introduction
- 6.2. Immunoassays
- 6.3. In-Situ Hybridization
- 6.4. Mass Spectrometry
- 6.5. Microarrays
- 6.6. Next-Generation Sequencing
- 6.7. Polymerase Chain Reaction
- 7. Cancer/Tumor Profiling Market, by Biomarker Type
- 7.1. Introduction
- 7.2. Genomic Biomarker
- 7.3. Protein Biomarker
- 8. Cancer/Tumor Profiling Market, by Cancer Type
- 8.1. Introduction
- 8.2. Breast Cancer
- 8.3. Colorectal Cancer
- 8.4. Lung Cancer
- 8.5. Melanoma Cancer
- 8.6. Prostate Cancer
- 9. Cancer/Tumor Profiling Market, by Application
- 9.1. Introduction
- 9.2. Biomarker Discovery
- 9.3. Clinical Application
- 9.4. Diagnostics
- 9.5. Personalized Medicine
- 9.6. Prognostics
- 9.7. Research
- 9.8. Screening
- 9.9. Treatment & Monitoring
- 10. Americas Cancer/Tumor Profiling Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Cancer/Tumor Profiling Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Cancer/Tumor Profiling Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. Market Share Analysis, 2023
- 13.2. FPNV Positioning Matrix, 2023
- 13.3. Competitive Scenario Analysis
- 13.3.1. Agilent and NCCS Sign Research Collaboration Agreement to Advance Singapore's Genomic Profiling on Asian-prevalent Cancers
- 13.3.2. Sophia Genetics, Agilent Partner on Cancer Analysis Product
- 13.3.3. Point32Health and Foundation Medicine Expand Access to Comprehensive Genomic Profiling for Members with Advanced Cancer
- 13.3.4. Synergy Laboratories Taps SOPHiA GENETICS Technology for New Cancer Profiling Solution
- 13.3.5. Exact Sciences Launches OncoExTra Cancer Therapy Selection Test in the U.S.
- 13.3.6. Caris Life Sciences nears USD 2B in total funding with USD 400M haul
- 13.3.7. Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco
- 13.3.8. Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
- 13.3.9. Prenetics Acquires ACT Genomics
- 13.3.10. Roche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for Enhertu
- 13.3.11. CDC Awards USD 215 Million to Advance Cancer Moonshot Goals
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.2. Key Product Portfolio
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
